Učitavanje...
Discovery of a Potent Dual ALK and EGFR T790M Inhibitor
The mutational activations of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) are validated oncogenic events and the targets of approved drugs to treat non-small cell lung cancer (NSCLC). Here we report highly potent dual small molecule inhibitors of both ALK and EGFR, p...
Spremljeno u:
| Izdano u: | Eur J Med Chem |
|---|---|
| Glavni autori: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5800871/ https://ncbi.nlm.nih.gov/pubmed/28528303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejmech.2017.04.079 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|